Pulse Biosciences updates investor deck with nPulse catheter development, cites 'unprecedented' EU feasibility data

PULSE BIOSCIENCES, INC.

Updated investor presentation posted on website includes summary financial info and product development update.
Next-generation nPulse cardiac catheter under development is highlighted.
Company strengthening focus on EP cardio ablation following 'unprecedented' EU feasibility study outcomes.
Presentation to be used in meetings with investors and analysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.